![]() |
|
|
Vol. 28, Issue 12, 1405-1410, December 2000
Université de Lausanne, Institut de Chimie Thérapeutique, Ecole de Pharmacie, Lausanne, Switzerland (M.R., M.R.-d.V., J.M.M., P.-A.C., B.T.); Sanofi Synthélabo, Montpellier, France (J.-P.M.); and Sanofi Synthélabo, Chilly Mazarin, France (Y.B.)
| |
Abstract |
|---|
|
|
|---|
Clopidogrel hydrogen sulfate, a thienopyridine derivative, is an ADP receptor antagonist that inhibits platelet aggregation. Clopidogrel is an enantiopure carboxylic ester of S-configuration. The R-enantiomer is devoid of antithrombotic activity and can provoke convulsions at high doses in animals. During preclinical safety evaluation, the possible chiral inversion of clopidogrel has, therefore, been investigated in vivo after repeated oral administration of different dose levels of clopidogrel to male and female rats. Due to rapid metabolism in the liver and low plasma levels of unchanged drug, possible chiral inversion was assessed by monitoring the plasma concentrations of the carboxylic acid metabolites, i.e., the (S)- and (R)-acid, by means of a stereoselective assay. The production of 4 to 8% of (R)-acid was observed. This could be the result of chiral inversion of either clopidogrel or its main metabolite, the (S)-acid. Thus, the possibility of nonenzymatic and enzymatic inversion of clopidogrel and its carboxylic acid metabolite was studied in vitro by chiral HPLC and 1H NMR. Nonenzymatic chiral inversion of clopidogrel at 37°C in 0.1 M phosphate buffers could be observed but was found to be slow, with estimated half-lives of 7 to 12 days, depending on the pH. The (S)-acid was configurationally fully stable up to 45 days in phosphate buffers. Neither clopidogrel nor its carboxylic acid metabolites were subject to enzymatic chiral inversion in isolated rat hepatocyte suspensions. We conclude that the nonenzymatic inversion of clopidogrel accounts for the 4 to 8% of chiral inversion seen in vivo in the rat.
| |
Introduction |
|---|
|
|
|---|
Clopidogrel hydrogen sulfate, methyl
(+)-(S)-
-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-acetate
hydrogen sulfate, is a thienopyridine derivative chemically related to
ticlopidine (see Fig. 1). Clopidogrel (Plavix/Iscover) is
indicated for the reduction of atherosclerotic events (myocardial
infarction, stroke, and vascular death) in patients with
atherosclerosis documented by recent stroke, recent myocardial
infarction, or established peripheral arterial disease (Plavix/Iscover,
data on file). Clopidogrel is inactive in vitro and the active
metabolite of the drug inhibits ADP-induced platelet aggregation by
direct inhibition of ADP binding to its receptor and therefore by
inhibition of the subsequent ADP-mediated activation of the
glycoprotein GIIb/IIIa complex (Gachet et al., 1992
; Humbert et al.,
1998
).
Clopidogrel is a chiral drug with S-configuration. It is
rapidly absorbed and undergoes extensive metabolism and metabolic activation in animals and humans. Hydrolysis of the ester function by
carboxylesterase leads to the carboxylic acid derivative with S-configuration (see Fig. 1), which is the main circulating
metabolite (about 85% of the circulating drug-related compounds in
plasma). Furthermore, clopidogrel is oxidized on the thiophene ring by cytochrome P450-1A in the liver (Herbert et al., 1993
; Plavix/Iscover, data on file). Experiments performed in vivo in the rat showed that
clopidogrel bioactivation occurred in the liver via the oxidative pathway (Savi et al., 1992
, 1994
).
The R-enantiomer is devoid of antithrombotic activity and
can evoke convulsions at high doses in animals (Gardell, 1993
). During
safety evaluation in animals, special attention was, therefore, required due to a possible chiral inversion of clopidogrel. Figure 1 illustrates the potential reactions of
chiral inversion and hydrolysis considered in this study. First, chiral
inversion of clopidogrel has been investigated in vivo after repeated
oral administration of different dose levels of clopidogrel hydrogen sulfate to male and female rats. Because of the low plasma levels of
unchanged drug (Herbert et al., 1993
), a possible chiral inversion of
clopidogrel was assessed by monitoring the plasma concentrations of its
carboxylic acid derivatives with S- and
R-configuration, using a stereoselective assay. To get
further insights, the nonenzymatic (i.e., chemical) inversion of
clopidogrel was studied by chiral HPLC and by 1H
NMR [1H/2H substitution
according to Kawazoe and Ohnishi (1964)
, Testa (1973)
, Reist et al.
(1995
, 1996
)], and the effects of pH, buffer concentration, ionic
strength, and polarity of the solvent were examined. The
configurational stability of the (S)-acid was verified by
1H NMR, although its nonenzymatic inversion is
highly improbable, because a free carboxy group is known to strongly
increase the configurational stability of chiral carbon atoms of the
type R"R'RC-H (Testa et al., 1993
; Reist et al., 1997
). The enzymatic
inversion of clopidogrel and its carboxylic acid derivatives was
investigated in isolated rat hepatocyte suspensions. A number of
anti-inflammatory 2-arylpropionic acids are well known to invert
configuration via their CoA1
thioester conjugate (Knihinicki et al., 1989
; Mayer, 1990
). Thus, the
possibility that the (S)- and/or (R)-acid
metabolites of clopidogrel invert via a similar mechanism was
investigated.
|
| |
Materials and Methods |
|---|
|
|
|---|
Chemicals.
Clopidogrel hydrogen sulfate, the hydrogen sulfate of its
R-enantiomer, and the hydrochlorides of their carboxylic
acid derivatives [(S)-acid and (R)-acid] were
supplied by Sanofi Recherche (Montpellier, France). Their optical
purities were 98.9, 98.2, 94.3, and 95.2%, respectively.
-(2-Methylphenyl)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-acetic acid was also supplied by Sanofi Recherche.
(S)-(+)-Ibuprofen was generously donated by the
Boots Co. Ltd. (Nottingham, England). BSA (fraction V) was purchased
from Fluka Chemie AG (Buchs, Switzerland). Collagenase
(Clostridium histolyticum type IV), EGTA,
(S)-(
)-
-(1-naphthyl)ethylamine (enantiomeric
excess >98%), 1-hydroxybenzotriazole (HOBT), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDAC) were obtained from
Sigma Chemical Co. (St. Louis, MO). The deuterated solvents were
purchased from Armar (Döttingen, Switzerland), and their isotopic
purities were: D2O 99.8 atom%D,
DMSO-d6 99.8 atom%D, and
CD3CN 99.8 atom%D. All other chemicals were of
analytical grade and used without further purification.
In Vivo Chiral Inversion in Rats.
Animals This study was conducted in compliance with the principles of Good Laboratory Practice. At the beginning of the treatment period, Crl CD (SD) BR rats (Charles River, Saint-Aubin-les-Elbeuf, France) were approximately 6 weeks old and had mean body weights of 192 g and 159 g for males and females, respectively. During the study, the animals were housed in suspended wire-mesh cages (43.0 × 21.5 × 18.0 cm), and each cage contained two rats of the same sex and group. The animal rooms had a temperature range of 19-23°C, a relative humidity range of 30 to 70%, and a light/dark cycle of 12 h. Animals had free access to diet (A04 C diet, U.A.R., Villemoisson-sur-Orge, France) and to tap water filtered with a 0.22-µm filter (Millipore S.A., Vélizy, France).
Study design.
After clinical examination to ensure animals were in good health, 96 male and 96 female rats were assigned to four experimental groups
receiving different levels of clopidogrel hydrogen sulfate (10, 35, 100, and 160 mg/kg/day). The drug was administered in the diet during 4 weeks. The concentration of clopidogrel hydrogen sulfate in the diet
was modified every week according to body weight and food consumption
data, to maintain the adequate dose levels for each group. To determine
the exposure at steady-state after 4 weeks, blood samples were
collected every 3 h from day 27 at 7:00 PM to day 28 at 7:00 PM,
i.e., on day 27 at 7:00 and 10:00 PM, and on day 28 at 1:00, 4:00,
7:00, and 10:00 AM and at 1:00, 4:00, and 7:00 PM.
AUC0-24 h values were calculated from 7:00 PM
on day 27 to 7:00 PM on day 28. This 24-h period corresponded to a
light/dark cycle (12 h/12 h) in animal rooms. At each sampling time,
blood samples were collected from four individual males and four
individual females per experimental group. To reduce the total number
of animals, for half of the rats per group, two blood samples were
withdrawn from the same animal with an interval period of 12 h.
Blood was collected in tubes containing lithium heparin as an
anticoagulant, from the orbital sinus of the animals under slight ether
anesthesia. After centrifugation, plasma samples were stored at
20°C until assayed for (S)-acid and (R)-acid.
Analytical method.
After addition of
-(2-methylphenyl)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-acetic
acid as internal standard (5 µg), the stereoselective analysis of the
(S)-acid and (R)-acid was carried out as follows. The extraction and derivatization procedures were modifications of the
method of Hutt et al. (1986)
. Briefly, to an aliquot of plasma (0.25 ml) acetate buffer, pH 5 (0.75 ml), and acetonitrile (0.25 ml) were
added. This solution was placed on top of an Extrelut-1 column (Merck,
Darmstadt, Germany). A first elution with hexane (5 ml) was discarded,
and analytes were eluted with
CH2Cl2 (5 ml). After
evaporation of the solvent, the dry residue was reconstituted in
CH2Cl2 (1 ml) and
derivatized with
(S)-(
)-
-(1-naphthyl)ethylamine (0.1 ml of a
6 mg/ml solution in CH2Cl2)
in the presence of HOBT (0.1 ml of a 1.5 mg/ml solution in
CH2Cl2) and EDAC (0.1 ml of a 1.5 mg/ml solution in
CH2Cl2). After a 16-h
incubation at room temperature, water (4 ml) and hexane (3 ml) were
added. The two phases were separated, and the organic phase reduced to
dryness at room temperature under a stream of nitrogen. The dry residue was dissolved in the HPLC mobile phase (20 µl).
Data analysis.
Concentrations of (S)- and (R)-acid were
expressed as unsalified compounds. On days 27 and 28, population
estimates of AUC0-24 h and their standard
errors were calculated for each dose level by sex combination using the
linear trapezoidal rule on average concentration at each sampling time
(Yeh, 1990
). Considering the composite design adopted for blood
samplings, the terminology "population estimates" has been used.
For all estimates, 95% confidence intervals were calculated from the
standard error of the estimate, and degrees of freedom were determined
using the Satterthwaite procedure.
Nonenzymatic Chiral Inversion and Hydrolysis Monitored by HPLC. In aqueous solutions at physiological pH, clopidogrel hydrogen sulfate is very slightly soluble (<0.001 mg/ml), and a cosolvent (methanol) had to be used to investigate its nonenzymatic chiral inversion and hydrolysis by HPLC.
Three mixtures of methanol with phosphate buffer pH 7.4 (0.2 M, ionic strength 0.52), in the proportions 1:1, 2:3, and 1:2 (v/v) were prepared to assess the influence of methanol concentration. The influence of pH was investigated by measuring reaction rates in 1:1 (v/v) mixtures of methanol and phosphate buffers (0.1 M, ionic strength 0.3) of four different pH values, pH 3.0, 5.6, 7.4, and 9.0. To study the influence of buffer concentration, 1:1 (v/v) mixtures of methanol and phosphate buffers (pH constant at 7.4, ionic strength 0.78) of three different concentrations (0.1, 0.2, and 0.3 M) were prepared. Mixtures (1:1, v/v) of methanol and phosphate buffers (pH 7.4, 0.2 M) of three different ionic strengths (0.52, 0.6, 0.78) were prepared to investigate the influence of ionic strength. Clopidogrel hydrogen sulfate (30 mg, 7.738 × 10
5 M) was dissolved in 100 ml of the solvent
mixtures described above. Each solution was placed in a 100-ml bottle
with a crown cap and kept in a rotating water bath at 37 ± 0.2°C. Kinetic studies were performed by repeated sampling of 0.2-ml
reaction mixture followed by HPLC analysis over a time interval of 78 days.
To observe a possible esterification of the (S)-acid, 1:1
(v/v) mixtures of methanol and phosphate buffers (0.1 M, ionic strength 0.3) of pH 7.4 and pH 9.0 were prepared. The (S)-acid
hydrochloride (30 mg, 8.309 × 10
5) was
dissolved in 100 ml of solvent mixture, and the solutions were handled
like the clopidogrel solutions. Analyses were performed over a time
interval of 42 days.
Analytical methods.
To monitor chiral inversion, clopidogrel and its enantiomer were
separated on a Nucleodex
-PM column 150 × 4.6 mm
(Macherey-Nagel, Düren, Germany), using the mobile phase
methanol/triethylammonium acetate buffer, pH 4.0, 0.1% (65:35, v/v), a
flow rate of 0.7 ml/min, and UV detection at 230 nm. The retention
times of clopidogrel and its enantiomer were 19.1 and 22.1 min, and the
detection limits 2 and 2.5 mg/l, respectively.
Data analysis.
The apparent pseudo first order rate constants of chiral inversion of
clopidogrel (kS-to-R) were
calculated according to eq. 1:
|
(1) |
|
(2) |
Nonenzymatic Chiral Inversion Monitored by 1H NMR.
The configurational stability of clopidogrel and its carboxylic acid
derivative, the (S)-acid, was monitored by
1H NMR
(1H/2H substitution). The
method takes advantage of the fact that the inversion of chiral centers
of the type R"R'RC-H and proton-deuterium exchange share a common
mechanism (Kawazoe and Ohnishi, 1964
; Testa, 1973
; Reist et al., 1995
,
1996
). Briefly, when a compound having a chirally labile C-H group is
dissolved in D2O, the proton is irreversibly
replaced by a deuterium, and deuteration can be followed by integrating
the signal of the exchanging proton. The 1H NMR
spectra and integrals were recorded on a Varian VXR-200 NMR
spectrometer operating at 200 MHz (Varian Associates Inc., Palo Alto, CA).
Clopidogrel.
For clopidogrel, the four media investigated consisted of
D2O (pD 1.7),
DMSO/D2O (2:1),
CD3CN/D2O (1:1), and
DMSO/phosphate buffer pD 7.4, 0.2 M (2:1). Clopidogrel hydrogen sulfate
(20 mg, 5.159 × 10
5 M) was dissolved in 1 ml of solvent. Each such solution was placed in a NMR tube and kept in
a water bath at 37 ± 0.2°C. At various time intervals up to 116 days, 1H NMR spectra and integrals were recorded
at 37°C.
(S)-Acid.
20 mg (5.539 × 10
5 M) of
(S)-acid hydrochloride were dissolved in 1 ml of phosphate
buffer pD 7.4, 0.2 M, or in 1 ml of D2O adjusted
to a pD of 12 with NaOD. Each solution was placed in a NMR tube
and kept at 50 ± 0.2°C in a water bath. At various time
intervals up to 45 days 1H NMR spectra and
integrals were recorded at 50°C.
Data analysis.
For clopidogrel, the sum of the rate constants of deuteration and
hydrolysis (kdeut + khyd) was calculated according to eq. 3:
|
(3) |
|
(4) |
Enzymatic Chiral Inversion and Hydrolysis in Rat Hepatocyte Suspensions.
Animals The male Sprague-Dawley rats (200-300 g, BRL, Füllinsdorf, Switzerland) used to provide hepatocytes were kept in an air-conditioned environment (21.5°C, 50% humidity), on a normal 12-h light/dark cycle. The animals had free access to water and food (Nafag Futter, Nafag, Gossau, Switzerland) until the morning of sacrifice.
Preparation of rat hepatocyte suspensions.
Rat hepatocytes were isolated by a two-step collagenase (Clostridium
histolyticum type IV) perfusion of the liver as reported previously (Seglen, 1975
; Roy-de Vos et al., 1996
). The cells (5 × 105 cells/ml) were resuspended in Hanks'
buffer containing 0.5% BSA (fraction V) (Hanks and Wallace, 1949
).
Incubation conditions. After addition of the substance under investigation (either clopidogrel, the (S)-acid, or the (R)-acid), incubations were carried out for 4 h at 37°C under agitation in an air/CO2 (95:5; v/v) atmosphere (CO2 of medicinal grade; Carbagaz SA, Lausanne, Switzerland). Cell viability, determined by Trypan Blue exclusion, was routinely greater than 85%.
Every 30 min, 5 ml of cell suspension was removed. One-half of each sample was treated for the stereoselective analysis of (S)-acid and (R)-acid to detect a possible chiral inversion, and the other half for the nonstereoselective analysis of clopidogrel and its carboxylic acid derivatives to assess hydrolysis. The cells were separated by centrifugation, and the supernatant was collected. For the stereoselective analysis of the acid derivatives, an internal standard, (S)-ibuprofen (60 µg/sample), was added to the supernatant and all samples were freeze-dried.Analytical methods. For the nonstereoselective analysis of clopidogrel and its acids, the freeze-dried residue from a 2.5-ml sample was dissolved in 1 ml of methanol, mixed thoroughly for 10 s and centrifuged. Twenty microliters of the supernatant were injected for HPLC analysis on a Supelcosil LC-ABZ column as described above (under Nonenzymatic Chiral Inversion and Hydrolysis Monitored by HPLC). Because the sample preparation was very simple, the addition of an internal standard proved unnecessary. The lowest concentration detected in the incubation medium was approximately 1 mg/l for the acids and 3 mg/l for the esters.
The stereoselective analysis of the (S)-acid and (R)-acid was carried out as follows. The extraction and derivatization procedures were modifications of the methods of Hutt et al. (1986)
)-
-(1-naphthyl)ethylamine (0.2 ml of a 1 mg/ml
solution in CH2Cl2) in the
presence of HOBT (0.1 ml of a 1 mg/ml solution in
CH2Cl2) and EDAC (0.2 ml of
a 1 mg/ml solution in
CH2Cl2) to form the
diastereomeric amides of the (S)- and (R)-acid.
The residue was dissolved in 0.3 ml of water and analyzed by HPLC on a
5 µm Nucleosil 50 column (250 × 4 mm, Knauer, Berlin,
Germany). The mobile phase consisted of hexane/ethyl acetate (85:15,
v/v) delivered at a flow rate of 1.0 ml/min. The naphthylethylamides of
the (R)- and (S)-acid and of the internal
standard (S)-ibuprofen eluted at 7.6, 8.5, and 9.4 min,
respectively. The lowest concentration of each enantiomer detected in
the incubation medium was 0.2 mg/l.
Data analysis. A two-compartmental model with elimination from both compartments was used to investigate the hydrolysis of clopidogrel in rat hepatocyte suspensions, with kAB designating the first order rate constant of hydrolysis of clopidogrel, and kA and kB the first-order rate constants of the nonhydrolytic elimination of clopidogrel and the (S)-acid, respectively. Data analysis was carried out with a nonlinear regression program (Siphar, Simed S.A., Créteil, France).
| |
Results |
|---|
|
|
|---|
In Vivo Chiral Inversion in Rats. Clopidogrel hydrogen sulfate administered orally (in the diet) to rats at dose levels of 10, 35, 100, and 160 mg/kg/day over a 4-week period was well tolerated by all animals, and no clinical signs of adverse reaction to the treatment were observed. From food consumption, the achieved dosages were in good agreement with the nominal dosage for each sex and at all dose levels, throughout the study. Overall mean values were 10.2, 35.2, 99.4, and 160.7 mg/kg/day in males, and 9.8, 33.6, 96.7, and 154.5 mg/kg/day in females.
Due to low plasma levels of unchanged drug (Savi et al., 1992
|
Nonenzymatic Chiral Inversion and Hydrolysis Monitored by HPLC. Estimated half-lives of nonenzymatic chiral inversion and hydrolysis of clopidogrel in the investigated media were between 3.5 and 8.5 weeks, and 3 and 36 months, respectively. The influences of methanol concentration, pH, phosphate concentration, and ionic strength on the rate constants of chiral inversion and hydrolysis are shown in Table 2. The rates of inversion and hydrolysis decreased with increasing methanol concentration and were pH-dependent. The chiral inversion was slower in acidic solutions than in neutral or basic media, and the hydrolysis showed a minimum at a pH around 5 and increased in acidic and in alkaline media. The rates of both reactions were proportional to the phosphate concentration.
|
|
Nonenzymatic Chiral Inversion Monitored by 1H NMR.
1H NMR has previously been shown to be a suitable
tool to assay inversion of chiral centers of the type R"R'RC-H (Kawazoe
and Ohnishi, 1964
; Testa, 1973
; Reist et al., 1995
, 1996
). The rates of
deuteration of clopidogrel in different solvents at 37°C are shown in
Table 4. Deuteration and, therefore,
chiral inversion of clopidogrel in all solvents were found to be low.
In fact, the estimated half-lives of deuteration were between 1 and 8 months.
|
Enzymatic Chiral Inversion and Hydrolysis in Rat Hepatocyte Suspensions.
Incubations of clopidogrel Isolated rat hepatocytes were incubated with different concentrations of clopidogrel (25, 50, and 100 mg/l) and the formation of the (S)- and (R)-acid was monitored. Only the (S)-acid, the carboxylic acid derivative with the same configuration as clopidogrel, was detected at all concentrations investigated. The concentration of the (S)-acid increased with time and reached maximal levels of 7 to 15 mg/l, depending on the initial concentration of clopidogrel. Because the detection limit of each enantiomer in the incubation medium was 0.2 mg/l, it can be deduced that there was less than 1 to 2% of chiral inversion of clopidogrel occurring in rat hepatocyte suspensions.
The hydrolysis of clopidogrel in rat hepatocyte suspensions is illustrated in Fig. 2, showing the rapid decrease of clopidogrel (25 mg/l) with a simultaneous increase in concentration of the (S)-acid. The rate of hydrolysis of clopidogrel (kAB = 0.52 ± 0.028 h
1) is slower than its nonhydrolysis
elimination (kA = 0.82 ± 0.049 h
1). In rat hepatocyte suspensions,
approximately 39% of the initial concentration of clopidogrel was
hydrolyzed to its carboxylic acid metabolite with
S-configuration. It can further be noted that the
time-concentration profile of (S)-acid after incubation of
25 mg/l of clopidogrel, determined with the nonstereoselective method,
was identical to that obtained with the stereoselective method.
|
Incubations of the (S)-acid and
(R)-acid.
At incubations of either the (S)-acid or (R)-acid
(10 mg/l) no formation of the antipodes could be detected during the
4 h of incubation, indicating a lack of enzymatic inversion of
(S)-acid to (R)-acid or vice versa. The
elimination of the acids was of first order, and no significant
difference in the rates of elimination of the enantiomers was observed.
Indeed, the elimination rate constants were 0.25 ± 0.010 and
0.26 ± 0.015 h
1 for the (S)-
and (R)-acid, respectively.
| |
Discussion |
|---|
|
|
|---|
Daily oral administration of different dose levels of clopidogrel (10-160 mg/kg/day) over a 4-week period to male and female rats resulted in production of 4 to 8% of the (R)-acid, the carboxylic acid derivative with configuration opposite to that of clopidogrel. Indeed, plasma levels of the (S)-acid were 12- to 25-fold higher than those of (R)-acid. Despite the fact that, at the 100 mg/kg/day dose level, the (R)- and (S)-acid AUC values were significantly greater for males than for females, a finding that deserves confirmation, the contribution of (R)-acid was independent of sex and constant over the dosing interval. This observed appearance of a small percentage of (R)-acid in the plasma could be the result of nonenzymatic or enzymatic chiral inversion of either clopidogrel or its main metabolite, the (S)-acid. To address this question further, investigations in vitro on the mechanism of chiral inversion of clopidogrel and its carboxylic acid derivatives were performed.
The nonenzymatic chiral inversion and hydrolysis of clopidogrel in all
investigated media were found to be slow. Both rates of reaction were
pH-dependent and decreased with increasing methanol concentration.
These findings are in good agreement with the fact that inversions of
chiral centers of the type R"R'RC-H and hydrolyses are in general acid-
and/or base-catalyzed processes (Isaacs, 1987a
; Reist et al., 1995
) and
thus expected to be pH-dependent. Also, both processes are thought to
proceed faster in aqueous than in methanolic solutions (Isaacs, 1987b
).
Both reaction rates were also found to be proportional to the phosphate
concentration. With a 3-fold increase in phosphate concentration, the
rate constant of chiral inversion increased 1.1-fold and that of
hydrolysis 1.3-fold. Hence, chiral inversion and hydrolysis of
clopidogrel followed a very weak general-base catalysis, in contrast to
the marked general-base catalysis seen in cases of ready racemization (Reist et al., 1995
, 1996
). Because the rates of chiral inversion and
hydrolysis decreased only very slowly with increasing ionic strength,
it can be deduced that phosphate concentration and ionic strength have
only a marginal influence on the chiral inversion and hydrolysis of clopidogrel.
Although the nonenzymatic chiral inversion of the (S)-acid
is improbable, due to the fact that a carboxy group is known to stabilize chiral carbon atoms of the type R"R'RC-H (Testa et al., 1993
;
Reist et al., 1997
), its configurational stability was investigated by
1H NMR. 1H NMR has
previously been shown to be a suitable tool to assay inversion of
chiral centers of the type R"R'RC-H (Kawazoe and Ohnishi, 1964
; Testa,
1973
; Reist et al., 1995
, 1996
). The method takes advantage of the fact
that the inversion of such chiral centers and proton-deuterium exchange
share a common mechanism. As expected, no deuteration was observed and
the configuration of (S)-acid was found to be stable up to
45 days in all media studied.
Enzymatic chiral inversion of clopidogrel and its carboxylic acid
derivatives was investigated in rat hepatocyte suspensions. In contrast
to nonenzymatic chiral inversion, which is of ubiquitous occurrence, only a limited variety of enzymatic reactions are known to
interconvert stereoisomers (Testa et al., 1993
). One of them is the
enzymatic chiral inversion of anti-inflammatory 2-arylpropionic acids
(Knihinicki et al., 1989
; Mayer, 1990
). The inactive
(R)-enantiomer of ibuprofen and a few analogues are enantioselectively conjugated with coenzyme A to yield the
(R)-acyl-CoA thioester. This conjugate is then epimerized to
a mixture of the (S)- and (R)-acyl-CoA, followed
by hydrolysis to yield a profen enriched in the (S)-form.
Because this reaction was observed in isolated rat hepatocyte
suspensions (Mayer et al., 1994
; Roy-de Vos et al., 1996
), the same
investigation medium was chosen to study the possibility that the
clopidogrel acids invert via a similar reaction mechanism. However, our
results show that neither clopidogrel nor its carboxylic acid
derivatives were subject to enzymatic chiral inversion in rat
hepatocyte suspensions. Indeed, when clopidogrel was incubated, only
the (S)-acid was formed, and when either (S)- or
(R)-acid were incubated, no formation of the corresponding
antipode could be observed.
In summary, the apparent rate constants of nonenzymatic chiral
inversion of clopidogrel at 37°C in phosphate buffers, the absence of
nonenzymatic chiral inversion of (S)-acid, and the lack of
enzymatic chiral inversion of clopidogrel and its carboxylic acid
derivatives in rat hepatocyte suspensions seem to be in good agreement
with the 4 to 8% of chiral inversion seen in rats. From our results we
deduce that nonenzymatic inversion of the ester, even if slow in the
investigated media, accounts for the 4 to 8% of chiral inversion
occurring in vivo in rats. To confirm our hypothesis, additional
experiments conducted in protein solution and plasma could be of
interest. Indeed, endogenous bases such as proteins, amines and amino
acids, thiolate groups, and carbonate can be expected to contribute to
an acceleration of the nonenzymatic chiral inversion (Reist et al.,
1995
). In humans, plasma levels of the (R)-acid were
consistently below the limit of detection (Necciari et al., 1996
) after
single oral administration of clopidogrel doses up to 150 mg.
In conclusion, the nonenzymatic inversion of clopidogrel demonstrated in vivo in rats during preclinical development has no clinical significance.
| |
Acknowledgments |
|---|
We are grateful to Dr. Christine Fabreguettes (Center International de Toxicologie, Evreux, France) for conducting the in-life phase in rats and to Dr. David Young (Sanofi Research Division, Alnwick, UK) for the statistical analysis of pharmacokinetic data.
| |
Footnotes |
|---|
Received May 16, 2000; accepted September 11, 2000.
Send reprint requests to: Bernard Testa, Université de Lausanne, Institut de Chimie Thérapeutique, BEP, CH-1015 Lausanne, Switzerland. E-mail: bernard.testa{at}ict.unil.ch
| |
Abbreviations |
|---|
Abbreviations used are: CoA, coenzyme A; AUC, area under the concentration versus time curve; Cmax, maximum concentration; EDAC, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide; HOBT, 1-hydroxybenzotriazole; DMSO, dimethyl sulfoxide; (R)-acid, carboxylic acid derivative of clopidogrel with R-configuration; (S)-acid, carboxylic acid derivative of clopidogrel with S-configuration; atom%D, percentage deuterium relative to total hydrogen in a given amount of compound.
| |
References |
|---|
|
|
|---|
)-1-(naphthen-1-yl)ethylamides.
J Chromatogr
378:
409-418[Medline].This article has been cited by other articles:
![]() |
T. A. Clarke and L. A. Waskell The Metabolism of Clopidogrel Is Catalyzed by Human Cytochrome P450 3A and Is Inhibited by Atorvastatin Drug Metab. Dispos., January 1, 2003; 31(1): 53 - 59. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||